Clinical trials: Alzheimer’s disease
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND002 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease.
- Indication: Patients with moderate to severe Alzheimer's disease with clinically significant agitation and aggression
- Purpose: Determine if ELND005 reduces symptoms of agitation and aggression after 12 weeks of treatment compared to placebo.
Principal Investigator: Michael Mega, M.D., Ph.D.
For more information, please contact Crystal Turner, CCRP at 503 216-1017